Currently out of the existing stock ratings of Liav Abraham, 54 are a BUY (78.26%), 13 are a HOLD (18.84%), 2 are a SELL (2.9%).

Liav Abraham

Work Performance Price Targets & Ratings Chart

Analyst Liav Abraham, currently employed at CITI, carries an average stock price target met ratio of 57.12% that have a potential upside of 15.8% achieved within 291 days.

Liav Abraham’s has documented 139 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ELAN, Elanco Animal Health at 15-May-2020.

Wall Street Analyst Liav Abraham

Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 5/1/2018. The price target of $24 was fulfilled within 42 days with a profit of $5.29 (28.27%) receiving and performance score of 6.73.

Average potential price target upside

of $9.62 (18.97%) on ZTS (ZOETIS).
of $8.32 (11.7%) on ENDP (ENDO INTERNATIONAL PLC).
of $5.76 (11.72%) on ALKS (ALKERMES PLC).

AGN Allergan plc ALKS Alkermes Plc ELAN Elanco Animal Health ENDP Endo International PLC HZNP Horizon Pharma PLC SGYP Synergy Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis JAZZ Jazz Pharmaceuticals PLC INSM Insmed MYL Viatris VTRS Viatris ACT Enact Holdings DBVT DBV Technologies

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gregg Gilbert (TRUIST)